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Abstract
Background: Inflammatory cells in the tumour stroma has gained increasing interest recently.
Thus, we aimed to study the frequency and prognostic impact of stromal mast cells and tumour
infiltrating eosinophils in invasive breast carcinomas.
Methods: Tissue microarrays containing 234 cases of invasive breast cancer were prepared and
analysed for the presence of stromal mast cells and eosinophils. Tumour infiltrating eosinophils
were counted on hematoxylin-eosin slides. Immunostaining for tryptase was done and the total
number of mast cells were counted and correlated to the proliferation marker Ki 67, positivity for
estrogen and progesterone receptors, clinical parameters and clinical outcome.
Results: Stromal mast cells were found to correlate to low grade tumours and estrogen receptor
positivity. There was a total lack of eosinophils in breast cancer tumours.
Conclusion: A high number of mast cells in the tumours correlated to low-grade tumours and
estrogen receptor positivity. Eosinophils are not tumour infiltrating in breast cancers.
Background
The stroma surrounding the malignant cells is important
for the growth and spread of the malignant tumour.
Recently, accumulating evidence suggests that the local
inflammatory process, previously believed to be the host
response against cancer, might actually contribute to the
development of malignancy and the inflammatory
response in the tumours has gained increased attention
[1-4]. In follicular lymphomas, gene expression analyses
have shown that genes associated with infiltrating inflam-
matory cells are more important than the tumour cells
themselves for predicting outcome [5].
Tumour-associated eosinophilia has been observed in
human cancers, sometimes with different results regard-
ing their association with clinical outcome [6-11].
Mast cells derive from a specific bone marrow progenitor
cell and migrate into tissues where they mature depending
on the microenvironmental conditions.
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Mast cells may promote tumour development through
many different ways. Mast cells could facilitate tumour
angiogenesis through heparin-like molecules and heparin
could further permit neovascularisation and metastases
through its anti-clotting effects [12]. Moreover, mast cells
secrete histamine and growth factors, such as VEGF (vas-
cular endothelial growth factor), PDGF (platelet derived
growth factor), SCF (stem cell factor) and NGF (nerve
growth factor). Mast cells are also rich in metalloproteases
that contribute to the majority of proteolytic components
necessary for tumour invasiveness [3]. On the other hand,
mast cells could also be detrimental to tumour growth by
secreting several cytokines and proteolytic enzymes partic-
ipating in inducing apoptosis of the malignant cells, such
as IL-4 [13]. The dual role of mast cells in inhibiting or
promoting tumour growth needs to be further investi-
gated [14]. Few studies of stromal mast cells in invasive
breast carcinomas have been done and two previous stud-
ies have indicated that many stromal mast cells are corre-
lated to a favourable prognosis [15-17]. Furthermore, in
lymph nodes of women with breast cancer a higher
number of mast cells were found in the non-involved axil-
lary lymph nodes in those women with a better prognosis
[18]. In women with axillary lymph node metastasis more
mast cells were found in the non-involved axillary lymph
nodes [19]. These findings might indicate a protective
effect of mast cells, possibly exerting a cytotoxic effect on
the tumour cells. However, the studies are still few and
further investigations are needed in order to elucidate the
precise role of mast cells in the tumourigenesis. Mast cells
interact with eosinophils in bidirectional interactions and
cytokine networks [20]. Eosinophils may serve as a source
of SCF which induces the growth of mast cells regulating
their activation, degranulation and chemotaxis.
In Hodgkin lymphomas, many eosinophils in the
tumours are correlated to an unfavourable prognosis [7]
and many mast cells have been associated with an adverse
clinical outcome [21]. Interactions between mast cells and
eosinophils in Hodgkin lymphomas are attributed to the
CD30L-CD30 interaction [22].
Tumour infiltrating eosinophils have previously been
investigated in colon carcinomas [6,8] but little data is
known about breast cancer. In colon cancer a high
amount of stromal eosinophils have correlated to a better
prognosis.
The aim of this study was to determine if the presence and
amount of tumour infiltrating mast cells and eosinophils
in breast cancer correlated to prognosis.
Methods
The patients were newly diagnosed breast cancer patients
collected in 1997–1998 at the Helsinki University Hospi-
tal as described previously [23]. Tissue microarray (TMA)
blocks were made from 234 cases of invasive breast cancer
as described [24,25]. For tissue microarray construction, a
hematoxylin and eosin stained section was made from
each paraffin block to define a representative tumour
region. The most representative area of the tumours was
punched to produce the TMA blocks including four cores
(diameter 0.6 mm) from each of the original blocks.
Immunohistochemistry
The formalin-fixed paraffin-embedded tissue material was
cut in 3–4 µm thick sections and deparaffinised. Immu-
nostainings for tryptase diluted 1:4000 (Chemicon Inter-
national) (mast cell specific, indicates the presence of all
mast cells both intact and degranulated mast cells in tis-
sues) were performed with an automatic immunostainer
(Ventana, Tucson AZ) at 37° using the avidin-biotin per-
oxidase complex and AEC procedures [26]. The peroxi-
dase was developed using the DAB technique. Primary
antibody was diluted 1:4000. Immunostaining results for
Ki 67, estrogen receptor (ER) and progesterone receptor
(PR) were collected from the pathology reports for all the
tumours. As negative control, only buffer and secondary
antibody was applied.
Mast cells and eosinophil counting
Mast cells and eosinophils were counted in one high-
power field (40× objective) in each tissue core and the
mean value of the cells present was estimated.
Statistical methods
All statistical analyses were made utilising Macintosh SPSS
11 statistical software package. The association between
mast cells, proliferation marker Ki 67, PR and ER was
tested by computing the nonparametric Spearman corre-
lation coefficient. Mast cells were included as a continous
variable as the mean number of the counted fields. Sur-
vival analysis with mast cell count as a continous variable
were performed with the Cox proportional hazard model.
Ethics
This study was approved by the Ethical Committee at Hel-
sinki University Hospital
Results
Two-hundred and thirty-four women were included in the
study. The median age was 54 years (range 27–95).
Tumour characteristics and staging is shown in table 1.
Patients were treated according to the recommended
guidelines in Helsinki University Hospital at that time.
In brief, all patients except one underwent surgery, mas-
tectomy in 121 and sector resection in 112. Postoperative
radiotherapy was given to 204 and adjuvant chemother-
apy to 92 patients. The chemotherapy regimen was CMFBMC Cancer 2007, 7:165 http://www.biomedcentral.com/1471-2407/7/165
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(cyclophosphamide, methotrexate and 5-fluorouracil) in
83 patients or FEC (cyclophosphamide, epirubicine and
5-fluorouracil) in 6 patients and three patients had other
chemotherapy regimen. Adjuvant endocrine therapy with
either tamoxifen (n = 82) or toremifen (n = 20) was given
to 102 patients.
Grading was done according to Elston-Ellis [27]. Sixty-five
(28%) were grade 1, 98 (42%) were grade 2 and 71 (30%)
were grade 3. (Table 1).
Twenty-two patients relapsed locally (localisation: chest
14 patients, axilla 5 patients and clavicular lymph nodes
3 patients). 58 patients developed distant metastasis. The
median follow-up time of surviving patients was 62
months (range 17–96).
Mast cells were found mainly in the tumour stroma adja-
cent to the neoplastic cells (fig 1) but in some cases mast
cells infiltrated within the islands of tumour cells.
Mean mast cell count was 7.3 (range 0–59). Eosinophils
were not present at all in any tumour. Mast cells correlated
significantly to low grade tumours (p = 0.001) and ER
positivity (p < 0.0005). There was no correlation to the
proliferation marker Ki 67. Mean mast cell count had no
significant impact on metastasis-free survival (p = 0.133,
relative hazard for high-versus low-mast 0.67, 95% confi-
dence level 0.40 – 1.13) (fig 2), overall survival (p = 0.17,
relative hazard 0.66, 95% CI 0.37–1.20) or local recur-
rence (p = 0.73, relative hazard 0.86, 95% CI 0.36–2.05).
Discussion
Identifying new prognostic markers for patients with
node-negative breast cancers is an important issue since
the current treatment guidelines recommend adjuvant
treatment for about 90 percent of the patients with node-
negative disease, even though only about 30 percent of
the patients actually will benefit from the therapy. Thus, it
is important to identify new markers for this subgroup of
patients who might then not need adjuvant chemother-
apy.
Table 1: Clinical and histological characteristics of all the patients with high (>mean 7.3) or low (<7.3) mast cell count.





Tumour stage (T) 0.462
1 129 (55) 69 60
2 89 (38) 45 44
37  ( 3 ) 4 3
47  ( 3 ) 5 2
not known 2 (1) 1 1
Axillary lymph node metastasis (N) 0.055
Present 118 (50) 66 52
Absent 114 (49) 58 56
Not known 2 (1) 0 2
Distant metastasis (M) at the time of diagnosis 0.656
Absent 208 (89) 110 98
Present 11 (5) 7 4
Not known 15 (6) 7 8
Histology 0.927
Ductal 163 (70) 80 83
Lobular 41 (17) 22 19
Mixed 26 (11) 20 6
Mucinous 3 (1) 2 1
Papillary 1 (1) 1 0
Elston-grading 0.001
1 65 (28) 44 21
2 98 (42) 55 43
3 71 (30) 25 46
Estrogenreceptorstatus <0.0005
Positive 179 (76) 105 74
Negative 44 (19) 15 29
Not known 11 (5) 4 7
Progesteronreceptorstatus 0.006
Positive 159 (68) 95 64
Negative 65 (28) 26 39
Not known 10 (4) 3 7BMC Cancer 2007, 7:165 http://www.biomedcentral.com/1471-2407/7/165
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The presence of mast cells was associated to low tumour
grade and estrogenreceptor positivity. These are factors
that are associated with a favourable prognosis in breast
cancer. This might, thus be interpreted as that many mast
cells is an additive favourable prognostic sign even though
it was not an independent prognostic marker in this study.
Eosinophils were not present at all in any of the tumour
samples.
Although the mast cell count did not have a statistical
impact on disease-free or overall survival in this study, this
may well be due to the small number of patients. A non-
significant trend towards both an improved local and dis-
tant tumour control was seen in patients with high mast
cell counts, as well as an improved survival. The magni-
tude of this putative prognostic impact, however, seemed
to be smaller than with classical clinical prognostic factors
like nodal status and tumour size [28].
Mast cells accumulate around tumours and could either
promote or inhibit tumour growth depending on the local
stromal conditions. The presence of stromal mast cells in
other malignant tumours have been of interest, but com-
prehensive studies are few. In colon cancer, a high amount
of mast cells have been associated with lower rates of
lymph node metastasis and distant metastasis [29] and
many eosinophils have been associated with a better prog-
nosis [6]. In lung cancers, a higher mast cell count has
been correlated to tumour progression [30] and also cor-
related to microvessel density [31] in some studies, but in
another study there was a lack of correlation between mast
cells, eosinophils and microvessels [32]. In squamous cell
carcinomas of the esophagus [33] and cervix [34] a high
number of mast cells in the tumours were likewise associ-
ated to both microvessel density and tumour progression.
Similarly, in malignant melanomas [35] and Hodgkin
lymphomas [21] mast cells have been related to an
adverse clinical outcome. The finding of many stromal
mast cells close to microvessel and the association to
microvessel density might be explained by contribution of
mast cells to neo-angiogenesis in these tumours. How-
ever, our finding of the correlation of large number of
mast cells to favourable prognostic factors in breast cancer
indicate that other factors must be taken into considera-
tion. Thus, the presence of stromal mast cells in different
tumours and their precise role in the tumourigenesis
needs to be further investigated in order to elucidate the
different mechanisms behind.
The absence of eosinophils indicates that other mecha-
nisms than the mast cell/eosinphil axis are involved, or
might rather indicate another composition of the inflam-
matory infiltrate in breast cancers.
Conclusion
The presence of stromal mast cells in breast cancer corre-
late to low grade tumours and estrogen receptor positivity.
The role of stromal mast cells for prognostic significance
in breast cancer warrants further studies. Eosinophils are
not tumour infiltrating in breast cancers.
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Mast cells express a dark brown immunoreactivity in the  cytoplasm Figure 1
Mast cells express a dark brown immunoreactivity in the 
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